Inclusion Criteria:

- Recipients of allogeneic stem cell transplantation with myeloablative or
non-myeloablative conditioning regimens

- Patients must be at least 180 days from the allogeneic stem cell transplantation
procedure

- Steroid refractory cGVHD, defined as having persistent symptoms and signs of GVHD
despite the use of prednisone for at least 4 weeks in the preceding 12 months without
complete resolution of signs and symptoms.

- Stable dose of corticosteroids for 4 weeks prior to enrollment

- No addition or subtraction of other immunosuppressive medications for 4 weeks prior
to enrollment.

- Adequate bone marrow, renal and hepatic function as outlined in the protocol

- 18 years of age or older

- ECOG Performance Status of 0-2

Exclusion Criteria:

- Ongoing prednisone requirement > 1mg/kg/day (or equivalent)

- Exposure to any new immunosuppressive medication in the 4 weeks prior to enrollment

- Concurrent ECP therapy within 4 weeks prior to enrollment

- Post-transplant exposure to any novel immunosuppressive medication within 100 days
prior to enrollment

- Donor lymphocyte infusion within 100 days prior to IL-2 therapy

- Active malignant disease relapse

- Active, uncontrolled infection

- Positive serologic test for Hepatitis B or a positive serologic or nucleic acid test
for Hepatitis C

- HIV seropositivity

- Life expectancy < 3 months

- Pregnancy or lactation

- Inability to comply with IL-2 treatment regimen

- Uncontrolled cardiac angina or symptomatic congestive heart failure

- Organ transplant (allograft) recipient